16 withdrawn. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Withdrawn 16 |
| Phase 2 | 4 | Withdrawn 4 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine Biomarker Validation Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg) - Treatment Resistant Depression (TRD) | Phase 1 | Withdrawn | Soterix Medical | 2025-12-20 | 2026-10-19 | |
| Repeated Neurocognitive Measurements in Depressed Patients Intravenous Ketamine - Depression, Unipolar | Phase 1 / Phase 2 | Withdrawn | Jay Fournier | 2025-05-01 | 2026-02-25 | |
| Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone Trazodone, Placebo - Postpartum Depression | Phase 1 | Withdrawn | Verinder Sharma | 2025-04-17 | 2025-04-04 | |
| Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST) MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT - Unipolar Depression | Phase 1 | Withdrawn | National Institute of Mental Health (NIMH) | 2025-02-26 | 2025-02-27 | |
| First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Fluoroethylnormemantine (FENM) - PTSD, Alzheimer Disease | Phase 1 | Withdrawn | ReST Therapeutics | 2024-05-02 | 2024-05-03 | |
| A Study of SDI-118 in Participants in Remission From Depression SDI-118, Placebo - Depression in Remission | Phase 1 | Withdrawn | Syndesi Therapeutics | 2021-09-16 | 2022-04-22 | |
| SSIPP vs. PST vs. WLC Student-Senior Isolation Prevention Partnership (SSIPP), Problem Solving Therapy (PST). - Major Depressive Disorder, Late Life Depression | Phase 1 | Withdrawn | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2021-08-09 | 2022-04-18 | |
| The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients Tadalafil 5Mg Tab, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-08-01 | 2025-07-14 | |
| The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients Roflumilast 500Mcg Tab, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2021-02-01 | 2025-07-14 | |
| Intravenous Ketamine Effects on Functional Neuroanatomy Ketamine - Depression | Phase 1 | Withdrawn | Neurological Associates of West Los Angeles | 2020-05-02 | 2020-06-01 | |
| The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients Vildagliptin 50 MG, Escitalopram 20 mg - Major Depressive Disorder | Phase 1 / Phase 2 | Withdrawn | Sadat City University | 2020-05-01 | 2025-07-14 | |
| Does rTMS Induce Synaptic Plasticity? [11C]UCB-J radiotracer, PET-MR - Major Depressive Disorder | Phase 1 | Withdrawn | Davidzon, Guido, M.D. | 2019-12-01 | 2024-12-02 | |
| Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression botulinum toxin A, Placebos - Major Depressive Disorder, Major Depressive Episode | Phase 1 | Withdrawn | Helse Stavanger HF | 2019-05-01 | 2021-08-11 | |
| Internet Intervention for the Prevention of Depression - Approaches to Improving Mood AIM Web based intervention + surveillance, AIM web based intervention, Educational website - Individuals at Risk for Depression | Phase 1 | Withdrawn | Northwestern University | 2012-06-01 | 2012-07-03 | |
| Brain Imaging, Genetics and Treatment for Major Depression Citalopram - Depressive Disorder, Depressive Disorder, Major | Phase 1 | Withdrawn | National Institute of Mental Health (NIMH) | 2012-03-12 | 2019-12-17 | |
| A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects CP-601,927, Placebo - Healthy | Phase 1 | Withdrawn | Pfizer | 2011-08-26 | 2018-10-30 |
Depressive Disorder, Major (12) · Depression (5) · Depressive Disorder, Treatment-Resistant (4) · Alzheimer Disease (1) · Brain Diseases (1) · Depression, Postpartum (1) · Mental Disorders (1) · Mood Disorders (1) · Stress Disorders, Post-Traumatic (1)
Mental Disorders (15) · Mood Disorders (15) · Behavior (5) · Behavioral Symptoms (5) · Central Nervous System Diseases (1) · Dementia (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Pregnancy Complications (1) · Puerperal Disorders (1) · Stress Disorders, Traumatic (1) · Tauopathies (1)
Ketamine (3) · Botulinum Toxins, Type A (1) · Citalopram (1) · Escitalopram (1) · Roflumilast (1) · Sodium Chloride (1) · Tadalafil (1) · Trazodone (1) · Vildagliptin (1) · fluoroethylnormemantine (1)
Sadat City University (3) · National Institute of Mental Health (NIMH) (2) · Davidzon, Guido, M.D. (1) · Helse Stavanger HF (1) · Jay Fournier (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Neurological Associates of West Los Angeles (1) · Northwestern University (1) · Pfizer (1) · ReST Therapeutics (1) · Soterix Medical (1) · Syndesi Therapeutics (1) · Verinder Sharma (1)
United States (6) · Egypt (3) · Canada (2) · Belgium (1) · United Kingdom (1)
Akshya Vasudev, MD (1) · David C. Mohr, Ph.D. (1) · Gonzalo Laje, M.D. (1) · Jong H Yoon, MD (1) · Katharine Smith, DM (1) · Maeve Duffy, PhD (1) · Sarah H Lisanby, M.D. (1) · Sheldon Jordan, MD (1) · Taylor Kuhn, PhD (1) · Verinder Sharma, MB (1)